RNA (Atrium Therapeutics) Common Stock: $0.02 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.15
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Common Stock?

Atrium Therapeutics RNA +3.21% 12 Common Stock is $0.02 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's quarterly common stock stayed the same from Sep. 2025 ($0.02 Mil) to Dec. 2025 ($0.02 Mil) but then declined from Dec. 2025 ($0.02 Mil) to Mar. 2026 ($0.02 Mil).

Atrium Therapeutics's annual common stock stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.02 Mil).

Atrium Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Common Stock Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Common Stock
0.00 0.00 0.02

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial 0.00 0.00 0.02 0.02 0.02
RNA
12GF Score
Atrium Therapeutics Inc RNA
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.02 Mil mean?
Atrium Therapeutics (RNA) has a Common Stock of $0.02 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Common Stock too high?
Atrium Therapeutics' current Common Stock is $0.02 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Common Stock compare to RNAC and KROS?
Atrium Therapeutics' Common Stock of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Common Stock is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Common Stock of $0.02 Mil. The current Common Stock is $0.02 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Common Stock is $0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.15
Price